Select Medical's Q4 2024: Contradictions Unveiled on IRF Trends, LTAC Margins, and Hurricane Impacts
Generated by AI AgentAinvest Earnings Call Digest
Friday, Feb 21, 2025 5:53 pm ET1min read
SEM--
These are the key contradictions discussed in Select Medical's latest 2024Q4 earnings call, specifically including: IRF occupancy trends, LTAC margins, outpatient rehab growth expectations, impact of Hurricane Helene on IRF, and labor cost management:
Financial Performance and Development:
- Select Medical reported an 8% combined revenue increase for the fourth quarter, with adjusted EBITDA growing by 4%, compared to the prior year.
- The company added 94 inpatient rehabilitation beds during the quarter, as part of their ongoing expansion plans.
- The strong financial performance was driven by growth in all three divisions and the completion of development projects, although start-up costs and hurricane-related impacts affected inpatient rehab margins.
Labor Cost and Utilization Improvements:
- The cost of agency nurses normalized, with SWB as a percentage of revenue decreasing from 57.6% in Q4 prior year to 56.9%, driven by controlling internal labor costs and increased net revenue per patient day.
- Nursing sign-on and incentive bonus dollars decreased by 15%, contributing to a 55.9% SWB as a percentage of revenue for the full year, a reduction from 57.2% in 2023.
Outpatient Rehab Segment Growth:
- The outpatient rehab division saw an 7% increase in revenue, a 4% rise in patient volume, and an 18% improvement in adjusted EBITDA compared to the prior year.
- Growth was attributed to rate improvements in commercial contracts and increased clinical productivity, offsetting declines in Medicare reimbursement.
Debt Refinancing and Leverage:
- The company completed a refinancing of $1.6 billion in debt, with proceeds used to pay down existing debt and reduce interest expenses.
- Select Medical's net leverage was 3.18x at December 31, 2024, as they strive to maintain leverage between 3 to 3.1x for 2025 and lower in subsequent years.
Financial Performance and Development:
- Select Medical reported an 8% combined revenue increase for the fourth quarter, with adjusted EBITDA growing by 4%, compared to the prior year.
- The company added 94 inpatient rehabilitation beds during the quarter, as part of their ongoing expansion plans.
- The strong financial performance was driven by growth in all three divisions and the completion of development projects, although start-up costs and hurricane-related impacts affected inpatient rehab margins.
Labor Cost and Utilization Improvements:
- The cost of agency nurses normalized, with SWB as a percentage of revenue decreasing from 57.6% in Q4 prior year to 56.9%, driven by controlling internal labor costs and increased net revenue per patient day.
- Nursing sign-on and incentive bonus dollars decreased by 15%, contributing to a 55.9% SWB as a percentage of revenue for the full year, a reduction from 57.2% in 2023.
Outpatient Rehab Segment Growth:
- The outpatient rehab division saw an 7% increase in revenue, a 4% rise in patient volume, and an 18% improvement in adjusted EBITDA compared to the prior year.
- Growth was attributed to rate improvements in commercial contracts and increased clinical productivity, offsetting declines in Medicare reimbursement.
Debt Refinancing and Leverage:
- The company completed a refinancing of $1.6 billion in debt, with proceeds used to pay down existing debt and reduce interest expenses.
- Select Medical's net leverage was 3.18x at December 31, 2024, as they strive to maintain leverage between 3 to 3.1x for 2025 and lower in subsequent years.
Discover what executives don't want to reveal in conference calls
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet